Search Published Scientific Projects Competitive Products and Technology Patents
Login
The Codexis CodeEvolver® directed evolution technology platform lays the groundwork for delivery of a fast, cost-advantaged process that results in the development of enzymes and microorganisms that are custom designed to enable the relevant manufacturing
Industry:
Chemical
Owner:
Codexis, Inc.
CodeXyme® cellulase, Codexis’ flagship bioindustrial product, is an efficient, high-performing enzyme package for biofuels and bio-based chemical end markets. CodeXyme® cellulase enzymes transform cellulosic biomass (the inedible portion of plants) int
Industry:
Chemical
Owner:
Codexis, Inc.
The principle of Genome engineering is simple: it involves modifying the genetic code of an individual or species for the purposes of understanding the way it works, producing of useful proteins or treating a disease. Genetics has demonstrated the link be
Industry:
Life Sciences
Owner:
Cellectis
The key for Cellectis is to engineer Meganucleases that are specific to the targeted site, so as to create “tailor-made” meganucleases for each gene of interest. This ability to produce a wide range of molecules specific to the genes targeted is the techn
Industry:
Life Sciences
Owner:
Celletics
The effective power of Genome engineering lies in its ability to insert the gene of interest in the chosen place. For many years, researchers’ methods were akin to “playing darts blindfolded”. They would study the effect of randomly inserted sequences, de
Industry:
Life Sciences
Owner:
Cellectis
We have prioritized DNA engineering and synthesis as a focal point for technological innovation. With this in mind, we offer an engineered hybrid enzyme that combines the long recognition sequence of a homing endonuclease with the cutting properties of a
Industry:
Pharma
Owner:
Celexion, LLC.
Celexion has created the next-generation, fully-human, full-length, naive IgG library for de novo discovery of therapeutically relevant antibodies. The library is based on clinically validated human germline families in combination with IgM-expressing B-
Industry:
Pharma
Owner:
Celexion, LLC.
The development risk involved in biologics necessitates mitigation techniques to ensure the best antibody or enzyme is being used. For this effort, Celexion developed the SECANT® platform, a high-throughput discovery and optimization system that is the f
Industry:
Pharma
Owner:
Celexion, LLC.
Recently, scientists at NTNU and SINTEF have isolated a new producer of the cytotoxic macrolactam BE-14106, originally described in 1992, from marine sediments. In collaboration with the University of Bergen and University of Uppsala, the compound was tes
Industry:
Pharma
Owner:
Biosergen AS
Based on the expertise in biosynthetic engineering Biosergen is currently running a development program for systemic fungal infections where a candidate drug has been selected, BSG005. The candidate drug is in pre-clinical development. Genes for biosynthe
Industry:
Pharma
Owner:
Biosergen AS
BioFab projects will be designed to produce broadly useful collections of standard biological parts that can be made freely available to both academic and commercial users, while also enabling the rapid design and prototyping of genetic constructs needed
Industry:
Research
Owner:
Biofab
We provide consulting services at the juncture of biology and other disciplines such as marketing, engineering, and investment.
Industry:
Research
Owner:
Biodesic LLC
Rapid production of grams of antibodies for in vivo studies and extensive experience with expression of complex proteins. Extensive experience in the multiparameter protein engineering of antibodies and enzymes, including affinity maturation to femtomola
Industry:
Life Sciences
Owner:
Bayer HealthCare
ATG's acceptor-donor plasmid systems for multigeneering (ToggleTec, MultiLabel) allow you to insert individual or multiple genes or gene cassettes into any single vector. To generate multi-gene plasmid construct, you may either concatenate them by togglin
Industry:
Life Sciences
Owner:
ATG: biosynthetics, GmbH
DNA and Peptide Libraries: Libraries of bio-molecules have become a useful tool in research and development, especially when intending to select a few relevant peptides, DNAs, or proteins from a gigantic pool of possible candidates. These libraries can ei
Industry:
Life Sciences
Owner:
ATG: biosynthetics, GmbH
Modular Molecular Systems: Combining Synthetic Bioinformatics with GeneCluster Designs for Multi-Protein Expression and Minimal Molecular Function. DNA Optimization: EvoMag combines Synthetic Bioinformatics with GeneCluster Designs for Multi-Protein Expre
Industry:
Life Sciences
Owner:
ATG: biosynthetics, GmbH
Gene synthesis gives researchers the freedom of generating any gene in the absence of genomic or cDNA. Extending the capability of oligonucleotide synthesis technology, gene synthesis is the method of choice for creating new genes and assembling artificia
Industry:
Life Sciences
Owner:
ATG: biosynthetics, GmbH
AquAdvantage® Salmon (AAS) include a gene from the Chinook salmon, which provides the fish with the potential to grow to market size in half the time of conventional salmon. In all other respects, AAS are identical to other Atlantic salmon. AAS is an envi
Industry:
Life Sciences
Owner:
AquaBounty Technologies Inc
AMG 145 is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). It is being investigated as a treatment for hyperlipidemia. Aranesp® is a recombinant human protein agonist of the erythropoietin receptor. Broda
Industry:
Pharma
Owner:
Amgen Inc
AMG 151 is a small molecule glucokinase activator. It is being investigated as a treatment for type 2 diabetes. AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative coliti
Industry:
Pharma
Owner:
Amgen Inc